Treatment and prevention of malaria
AssigneeOxford University Innovation Limited
InventorsSimon Draper, Matthew Higgins, Katherine Wright, Alexander Douglas
Life of this patent
Estimating the term…
Abstract
There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising fragments of Reticulocyte-binding protein Homologue 5 (PfRH5). In particular, the invention provides fragments of PfRH5 rationally designed on the basis of the PfRH5 crystal structure, wherein said fragments which lack disordered regions, particularly the flexible N-terminal region and/or flexible central linker.
Claims16
A viral vector, RNA vaccine or DNA plasmid that expresses a PfRH5 antigen, wherein the antigen is a basigin-binding discontinuous fragment of PfRH5 which lacks (i) the flexible N-terminal region of PfRH5 corresponding to amino acid residues 1 to 139 of SEQ ID NO:
- 1 or 2;
- and (ii) the flexible loop region corresponding to amino acid residues 248 to 296 of SEQ ID NO:
- 1 or 2;
- optionally wherein said viral vector, RNA vaccine or DNA plasmid, which expresses the basigin-binding discontinuous fragment of PfRH5, further comprises a signal peptide;
- optionally wherein the signal peptide directs secretion from human cells;
- optionally wherein the signal peptide is a mammalian signal peptide from tissue plasminogen activator.
A vaccine composition comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen, wherein said antigen is a basigin-binding discontinuous fragment of PfRH5 which lacks (i) the flexible N-terminal region of PfRH5 corresponding to amino acid residues 1 to 139 of SEQ ID NO:
- 1 or 2;
- and (ii) the flexible loop region corresponding to amino acid residues 248 to 296 of SEQ ID NO:
- 1 or 2.
Dependencies are inferred from the claim text.